| [1] |
Rinella M, Charlton M. The globalization of nonalcoholic fatty liver disease: Prevalence and impact on world health[J]. Hepatology, 2016, 64(1):19-22.
|
| [2] |
Festi D, Colecchia A, Sacco T, et al. Hepatic steatosis in obese patients: clinical aspects and prognostic significance[J]. Obes Rev, 2004, 5(1):27-42.
|
| [3] |
Izumi T, Shibata Y, Yamamoto T. The cytoplasmic surface structures of uncoated vesicles in various tissues of rat as revealed by quick-freeze, deep-etching replicas[J]. J Electron Microsc (Tokyo), 1989, 38(1):47-53.
|
| [4] |
Kim CA, Delepine M, Boutet E, et al. Association of a homozygous nonsense caveolin-1 mutation with Berardinelli-Seip congenital lipodystrophy[J]. J Clin Endocrinol Metab, 2008, 93(4):1129-1134.
|
| [5] |
Cohen AW, Razani B, Wang XB, et al. Caveolin-1-deficient mice show insulin resistance and defective insulin receptor protein expression in adipose tissue[J]. Am J Physiol Cell Physiol, 2003, 285(1):C222-C235.
|
| [6] |
Baudrand R, Gupta N, Garza A E, et al. Caveolin 1 Modulates Aldosterone-Mediated Pathways of Glucose and Lipid Homeostasis[J]. J Am Heart Assoc, 2016, 5(10):e003845.
|
| [7] |
Li M, Chen D, Huang H, et al. Caveolin1 protects against diet induced hepatic lipid accumulation in mice[J]. PLoS One, 2017, 12(6):e178748.
|
| [8] |
Pojoga LH, Underwood PC, Goodarzi MO, et al. Variants of the caveolin-1 gene: a translational investigation linking insulin resistance and hypertension[J]. J Clin Endocrinol Metab, 2011, 96(8):E1288-E1292.
|
| [9] |
PALADE GE. An electron microscope study of the mitochondrial structure[J]. J Histochem Cytochem, 1953, 1(4):188-211.
|
| [10] |
Li B, Zhang Z, Zhang H, et al. Aberrant miR199a-5p/caveolin1/PPARalpha axis in hepatic steatosis[J]. J Mol Endocrinol, 2014, 53(3):393-403.
|
| [11] |
Yoneda M, Hotta K, Nozaki Y, et al. Association between PPARGC1A polymorphisms and the occurrence of nonalcoholic fatty liver disease (NAFLD)[J]. BMC Gastroenterol, 2008, 8(1):27.
|
| [12] |
Adiels M, Taskinen MR, Boren J. Fatty liver, insulin resistance, and dyslipidemia[J]. Curr Diab Rep, 2008, 8(1):60-64.
|
| [13] |
Aharoni-Simon M, Hann-Obercyger M, Pen S, et al. Fatty liver is associated with impaired activity of PPARgamma-coactivator 1alpha (PGC1alpha) and mitochondrial biogenesis in mice[J]. Lab Invest, 2011, 91(7):1018-1028.
|
| [14] |
Estall JL, Kahn M, Cooper MP, et al. Sensitivity of lipid metabolism and insulin signaling to genetic alterations in hepatic peroxisome proliferator-activated receptor-gamma coactivator-1alpha expression[J]. Diabetes, 2009, 58(7):1499-1508.
|
| [15] |
Louet JF, Hayhurst G, Gonzalez FJ, et al. The coactivator PGC-1 is involved in the regulation of the liver carnitine palmitoyltransferase I gene expression by cAMP in combination with HNF4 alpha and cAMP-response element-binding protein (CREB)[J]. J Biol Chem, 2002, 277(41):37991-38000.
|
| [16] |
Vega RB, Huss JM, Kelly DP. The coactivator PGC-1 cooperates with peroxisome proliferator-activated receptor alpha in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes[J]. Mol Cell Biol, 2000, 20(5):1868-1876.
|
| [17] |
Schwer B, North B J, Frye R A, et al. The human silent information regulator (Sir)2 homologue hSIRT3 is a mitochondrial nicotinamide adenine dinucleotide-dependent deacetylase[J]. J Cell Biol, 2002, 158(4):647-657.
|
| [18] |
张爽，朱晓辉，卢新, 等. 非酒精性脂肪性肝病风险基因SIRT3的关联验证和体内过表达效应研究[J]. 第三军医大学学报, 2017(08):737-742.
|
| [19] |
Hirschey MD, Shimazu T, Jing E, et al. SIRT3 deficiency and mitochondrial protein hyperacetylation accelerate the development of the metabolic syndrome[J]. Mol Cell, 2011, 44(2):177-190.
|
| [20] |
Hirschey MD, Shimazu T, Goetzman E, et al. SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation[J]. Nature, 2010, 464(7285):121-125.
|
| [21] |
Lu Z, Chen Y, Aponte A M, et al. Prolonged fasting identifies heat shock protein 10 as a Sirtuin 3 substrate: elucidating a new mechanism linking mitochondrial protein acetylation to fatty acid oxidation enzyme folding and function[J]. J Biol Chem, 2015, 290(4):2466-2476.
|
| [22] |
Dittenhafer-Reed KE, Richards AL, Fan J, et al. SIRT3 mediates multi-tissue coupling for metabolic fuel switching[J]. Cell Metab, 2015, 21(4):637-646.
|
| [23] |
Cho EH. SIRT3 as a Regulator of Non-alcoholic Fatty Liver Disease[J]. J Lifestyle Med, 2014, 4(2):80-85.
|
| [24] |
Shi T, Fan GQ, Xiao SD. SIRT3 reduces lipid accumulation via AMPK activation in human hepatic cells[J]. J Dig Dis, 2010, 11(1):55-62.
|
| [25] |
Kong X, Wang R, Xue Y, et al. Sirtuin 3, a new target of PGC-1alpha, plays an important role in the suppression of ROS and mitochondrial biogenesis[J]. PLoS One, 2010, 5(7):e11707.
|